Breast Cancer: The Basics, the Hormone Connection, and the MHT Confusion

Breast Cancer Awareness, Part 1: The Basics, the Hormone Connection, and the MHT Confusion

🎀 Breast Cancer Awareness · Part 1 of 4

October is Breast Cancer Awareness Month, and I want to use it to do more than remind you to get a mammogram. Over four posts, I want to actually help you understand this disease — what it is, who it affects, and especially the deeply confusing question I’m asked more than almost any other: “Will taking hormones give me breast cancer?” The honest answer is more reassuring, and more interesting, than the headlines suggest.

Let’s start at the beginning, build up to the hormone question, and clear away some fear with facts.

What is cancer, really?

Your body is made of trillions of cells that normally grow, divide, and die in an orderly, tightly controlled way. Cancer begins when that control breaks down — when a cell accumulates genetic damage that lets it grow and divide without the usual “stop” signals. These rogue cells multiply, form a mass (a tumor), and can eventually invade nearby tissue and spread to other parts of the body (metastasis). Breast cancer is simply this process beginning in the cells of the breast — most often in the cells lining the milk ducts or the milk-producing lobules.

The different types of breast cancer

“Breast cancer” isn’t one disease — it’s an umbrella over several distinct types that behave differently and are treated differently. A few key distinctions:

By where it starts, and whether it has spread locally

• Ductal carcinoma in situ (DCIS) — the earliest, non-invasive form, confined to the milk ducts (“in situ” = “in place”). Highly treatable.
• Invasive ductal carcinoma (IDC) — the most common type, starting in a duct and growing into surrounding breast tissue.
• Invasive lobular carcinoma (ILC) — begins in the milk-producing lobules; the second most common invasive type.
• Less common types — including inflammatory breast cancer (aggressive, often without a distinct lump) and others.

By molecular “subtype” — this is what guides treatment

Modern breast cancer care is driven less by where the tumor is and more by its biology — specifically, which receptors it carries. This is where hormone receptor status comes in, and it’s worth understanding.

What “hormone receptor status” actually means:

When a breast tumor is biopsied, the lab tests whether its cells carry estrogen receptors (ER) and progesterone receptors (PR) — tiny docking sites that let the cell respond to those hormones. A tumor that is “ER-positive” uses estrogen as fuel to grow. This is hugely important for two reasons: it’s good news for treatment (we have excellent anti-estrogen medications, like tamoxifen and aromatase inhibitors, that starve these cancers), and it generally signals a better prognosis. About 3 in 4 breast cancers are hormone-receptor-positive. Hold onto this concept — it’s the key to understanding the hormone question below.

Breast cancer by the numbers (US women)

Statistics can frighten, but they can also ground us in reality. Here’s the current picture for women in the United States:

1 in 8 lifetime risk (~13%) of developing breast cancer

~322,000 new invasive cases expected in US women in 2026

62 median age at diagnosis

A few important points of perspective. Breast cancer is the most commonly diagnosed cancer in US women (about 30% of new cancer diagnoses) and the second-leading cause of cancer death in women, after lung cancer. But here’s the equally important other side: survival has improved dramatically, there are now more than 4 million breast cancer survivors in the US, and when caught early, the great majority of breast cancers are very treatable. The “1 in 8” figure is also a lifetime risk accumulated over many decades — a woman’s risk in any given year of midlife is far lower (for example, roughly 1 in 25 across the entire decade of her 50s).

The question everyone asks: “Do hormones cause breast cancer?”

This is where I spend a great deal of time with patients, because the fear here is enormous — and much of it is based on a 20-year-old headline that was misunderstood then and is still misquoted now. Let me walk you through it carefully, because the truth genuinely matters for your health decisions.

The 2002 bombshell — and what it actually studied

In 2002, a huge study called the Women’s Health Initiative (WHI) made worldwide headlines when one arm was stopped early over a signal of increased breast cancer risk. Millions of women stopped their hormone therapy overnight; prescriptions plummeted. What got lost in the panic was a crucial detail: the WHI studied two very different kinds of hormone therapy, and they had opposite results.

The distinction that changes everything

The WHI had two separate trials:

• Estrogen PLUS progestin (for women with a uterus, who need a progestogen to protect the uterine lining): this combination was associated with a modest increase in breast cancer risk.
• Estrogen ALONE (for women who’ve had a hysterectomy): this did not increase breast cancer risk — and with long-term follow-up (now ~20 years), it was actually associated with a significant reduction in both breast cancer incidence and breast cancer deaths.

In the long-term follow-up published in 2020, estrogen alone was linked to roughly a 23% lower breast cancer incidence (and significantly fewer breast cancer deaths), while estrogen-plus-progestin was linked to about a 29% higher incidence. Same study, opposite directions — depending on whether a progestin was added.

What this tells us

The emerging understanding is that the estrogen itself may not be the villain in the combined regimen — the progestin (specifically the older synthetic one used in the WHI, medroxyprogesterone acetate) appears to be the primary driver of the increased risk. This has real, practical implications: it’s part of why there’s growing interest in using micronized (body-identical) progesterone, which some evidence suggests may carry a more favorable breast profile than the older synthetic progestins, though longer-term data are still accumulating.

Keeping the risk in perspective

Even for estrogen-plus-progestin, it’s essential to understand how small the absolute risk is. The increase amounts to roughly under one additional breast cancer case per 1,000 women per year of use — a risk comparable to or smaller than everyday factors like drinking a glass or two of alcohol daily, being overweight, or being physically inactive. “Increased risk” sounds alarming in a headline; in absolute terms, for most women it is small — and it must always be weighed against the real, substantial benefits of hormone therapy for symptoms, bone, and quality of life.

An honest note on the complexity

I want to be straightforward: this isn’t entirely settled. The WHI was a randomized trial (our strongest kind of evidence), and it found estrogen-alone protective. But some large observational studies (like the Million Women Study and a major meta-analysis) have found small increases in risk with both types. Scientists are still reconciling these differences. What the major menopause societies conclude from the whole body of evidence is measured and reassuring: for most healthy women under 60 or within 10 years of menopause, the benefits of hormone therapy generally outweigh the risks, and the breast cancer risk — where it exists at all — is small and manageable. It is a personal decision, made with your physician, weighing your own history and priorities.

The bottom line

• Cancer is uncontrolled cell growth; breast cancer usually starts in the milk ducts or lobules and comes in several distinct types.
• Molecular subtype guides treatment: hormone-receptor-positive (the most common, ~3 in 4), HER2-positive, and triple-negative.
• “ER-positive” means a tumor feeds on estrogen — which actually opens the door to effective anti-hormone treatments and a generally better prognosis.
• ~1 in 8 US women will develop breast cancer in a lifetime; it’s common, but survival is high and there are 4M+ survivors.
• The hormone question, honestly: in the WHI, estrogen-plus-progestin modestly raised breast cancer risk while estrogen-alone lowered it. The progestin, not the estrogen, appears to be the main driver — and the absolute risk is small.
• For most women under 60 or within 10 years of menopause, the benefits of hormone therapy generally outweigh the risks. It’s an individual decision.

Knowledge is the antidote to fear. Understanding what breast cancer actually is — and what the hormone evidence really says — lets you make decisions from a place of clarity, not headlines.

If the hormone question has been weighing on you, it’s exactly the kind of thing worth talking through in the context of your own history and risk — rather than deciding based on a frightening headline. That’s a conversation I’m always glad to have.

Coming next in this series

Part 2. We’ll dig into breast cancer risk factors — which ones you can change and which you can’t — and how to understand your own personal risk. Stay tuned throughout October.

Selected References

1. Siegel RL, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1). (1 in 8 lifetime risk; ~322,000 new invasive cases; incidence trends.)
2. American Cancer Society. Breast Cancer Facts & Figures / Key Statistics, 2026.
3. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
4. Chlebowski RT, et al. Long-term influence of estrogen plus progestin and estrogen alone on breast cancer incidence: the WHI randomized trials (SABCS 2019). (Estrogen alone −23%; estrogen+progestin +29%.)
5. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
7. Estrogens and breast cancer: role of progestogens as the primary driver of combined-therapy risk (review). PMC12168202. 2025.
8. Anderson GL, et al. WHI estrogen-alone trial (conjugated equine estrogen vs placebo) — breast cancer outcomes. JAMA / Lancet Oncol.

This article is for educational purposes and reflects the state of the evidence at the time of writing; it is not a substitute for individualized medical advice. Hormone therapy decisions should be made together with your own clinician based on your personal and family history, symptoms, and preferences. Any new breast lump, skin or nipple change, or other breast concern should be evaluated promptly, regardless of your screening schedule. Statistics are population estimates and do not predict any individual’s outcome.